Clinical Trials on Leukemia Lymphocytic Acute (ALL) in Relapse

Total 6065 results

Memorial Sloan Kettering Cancer Center

Recruiting

A Study of CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia

Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Acute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia Refractory | Relapsed Acute Myeloid Leukemia

United States
Second Affiliated Hospital of Xi'an Jiaotong University
Nanjing Legend Biotech Co.

Terminated

Study Evaluating Safety and Efficacy of CAR-T Cells Targeting CD123 in Patients With Acute Leukemia

Acute Myeloid Leukemia | Acute Leukemia | Acute Leukemia in Relapse | Relapsed or Refractory Acute Leukemia

China
Xijing Hospital
Xi'An Yufan Biotechnology Co.,Ltd

Recruiting

CRISPR (HPK1) Edited CD19-specific CAR-T Cells (XYF19 CAR-T Cells) for CD19+ Leukemia or Lymphoma.

Lymphoma, B-Cell | CD19 Positive | Leukemia Lymphocytic Acute (ALL) in Relapse | Leukemia Lymphocytic Acute (All) Refractory

China
Zhejiang University
Yake Biotechnology Ltd.

Recruiting

CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies

Acute Lymphoblastic Leukemia, in Relapse | Multiple Myeloma in Relapse | Multiple Myeloma, Refractory | Non-Hodgkin's Lymphoma, Relapsed | Non-Hodgkin's Lymphoma Refractory | Acute Lymphocytic Leukaemia Refractory

China
Institut Paoli-Calmettes
INATHERYS

Recruiting

Study of Escalating Doses of INA03 Administered Intravenously as Single Agent in Adult Patients With Relapse/Refractory Acute Leukemia (INA03)

Acute Lymphoblastic Leukemia, in Relapse | Acute Myeloid Leukemia, in Relapse | Mixed Phenotype Acute Leukemia | Acute Lymphoblastic Leukemia Recurrent | Acute Myeloid Leukaemia Recurrent

France
Hospices Civils de Lyon

Completed

Early Palliative Care in Patient With Acute Leukaemia (Pablo Hemato)

Acute Leukaemia in Relapse

France
Stichting Hemato-Oncologie voor Volwassenen Nederland
Nordic CLL Study Group

Active, not recruiting

A Prospective, Multicenter, Phase-II Trial of Ibrutinib Plus Venetoclax in Patients With Creatinine Clearance >= 30 ml/Min Who Have Relapsed or Refractory Chronic Lymphocytic Leukemia (RR-CLL) With or Without TP53 Aberrations

Chronic Lymphocytic Leukemia in Relapse | Chronic Lymphocytic Leukemia in Remission

Netherlands, Belgium, Denmark, Finland, Norway, Sweden
St. Jude Children's Research Hospital
AbbVie; Gateway for Cancer Research; Karyopharm Therapeutics Inc

Recruiting

Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia

Refractory Acute Myeloid Leukemia | Acute Myeloid Leukemia, in Relapse | Acute Leukemia of Ambiguous Lineage in Relapse | Refractory Acute Leukemia of Ambiguous Lineage

United States
All India Institute of Medical Sciences, New Delhi

Unknown

A Prospective, Interventional Study Assessing Response to Cytarabine, Daunorubicin and Etoposide (ADE) for First Relapse of Paediatric Acute Myeloid Leukemia

Acute Myeloid Leukemia, in Relapse
University Hospital Tuebingen

Recruiting

Tafasitamab (MOR00208) in Pediatric Patients With Relapsed or Refractory Acute B Lineage Leukemia (Anti-CD19-ALL)

ALL, Childhood B-Cell | Acute Lymphoid Leukemia Relapse | Acute Lymphocytic Leukemia Refractory

Germany
University of Freiburg

Completed

Analysis of T Cell Metabolism in Relapsed AML Patients With DLIs and Bicanorm Treatment

Acute Myeloid Leukemia, in Relapse

Germany
Precision BioSciences, Inc.

Completed

Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLL

Lymphoma, Non-Hodgkin | Chronic Lymphocytic Leukemia | B-cell Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma | B-cell Non Hodgkin Lymphoma | Leukemia, Lymphocytic, Chronic | Non-Hodgkin's Lymphoma, Relapsed | Non-Hodgkin's Lymphoma Refractory | Chronic Lymphoid Leukemia in Relapse

United States
Grupo Cooperativo de Hemopatías Malignas

Completed

Ibrutinib, Obinutuzumab and Venetoclax for Patients With Chronic Lymphocytic Leukemia

B-Cell Chronic Lymphocytic Leukemia | B-Cell Chronic Lymphocytic Leukemia in Relapse (Diagnosis)

Mexico
Syndax Pharmaceuticals

Active, not recruiting

A Study of SNDX-5613 in Combination With Chemotherapy in Participants With R/R Acute Leukemia

Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Acute Lymphocytic Leukemia | Acute Undifferentiated Leukemia | Relapsed/Refractory Leukemias | Mixed Phenotype Acute Leukemia

United States, Canada
UNC Lineberger Comprehensive Cancer Center
Merck Sharp & Dohme LLC

Active, not recruiting

High Dose Cytarabine Followed by Pembrolizumab in Relapsed/Refractory AML

Acute Myeloid Leukemia, in Relapse

United States
Terrence J Bradley, MD
Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New...

Recruiting

Venetoclax and Bomedemstat in Patients With Relapsed/Refractory Acute Myeloid Leukemia (VenBom)

Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Acute Myeloid Leukemia, in Relapse

United States
Hospital Israelita Albert Einstein
Miltenyi Biotec, Inc.

Not yet recruiting

A Phase I Clinical Trial Using Genetically Engineered Autologous T Cells to Express Chimeric Antigen Receptor (CAR) for Treatment of Patients With Refractory or Relapsed CD19-positive B Lymphoid Malignancies (CARTHIAE-1)

Acute Lymphoblastic Leukemia, in Relapse | B-cell Lymphoma Refractory | B-cell Lymphoma Recurrent | Chronic Lymphocytic Leukemia Recurrent | Chronic Lymphocytic Leukemia Refractory | Acute Lymphoblastic Leukemia Refractory

Brazil
Peking University People's Hospital
Beijing JD Biotech Co. LTD.

Recruiting

Off-the-shelf CD123 CAR-NK for R/R AML

Acute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia Refractory

China
Xuzhou Medical University

Recruiting

Administration of Anti-siglec-6 CAR-T Cell Therapy in Relapsed and Refractory Acute Myeloid Leukemia (rr/AML)

Acute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia Refractory

China
Bio-Path Holdings, Inc.

Recruiting

A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia Refractory

United States
Xuzhou Medical University

Recruiting

Administration of Anti Tim-3/CD123 CAR-T Cell Therapy in Relapsed and Refractory Acute Myeloid Leukemia (rr/AML)

Acute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia Refractory

China
Aptose Biosciences Inc.

Terminated

A Study of APTO-253 in Patients With Relapsed or Refractory AML or MDS

Acute Myelogenous Leukemia | Acute Myelogenous Leukemia in Relapse | Acute Myelogenous Leukemia, Relapsed, Adult | Acute Myelogenous Leukemia, Adult | High Risk Myelodysplasia

United States
Beijing GoBroad Hospital

Not yet recruiting

CD5 Chimeric Antigen Receptor (CAR) T Cells in Subjects With Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia, in Relapse | Refractory Acute Lymphoblastic Leukemia | T-Cell Acute Lymphocytic Leukemia
Advesya SAS

Not yet recruiting

An Adaptive Open-label Multicentre Phase 1/2 Trial, to Determine the Recommended Phase 2 Dose of CCTx-001, and to Assess Safety, Tolerability, and Clinical Activity in Patients With Relapsed/Refractory Acute Myeloid Leukaemia (RESOLVE AML001)

Acute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia Refractory

France, Sweden, Spain, Germany
Keystone Nano, Inc
Milton S. Hershey Medical Center; University of Virginia

Not yet recruiting

Study of C6 Ceramide NanoLiposome (CNL) in Patients With Relapsed/Refractory Acute Myeloid Leukemia (KNAN2001)

Acute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia, Refractory

United States
Gruppo Italiano Malattie EMatologiche dell'Adulto

Recruiting

Venetoclax and Azacitidine for the Management of Molecular Relapse/Progression in Adult NPM1-mutated Acute Myeloid Leukemia

Acute Myeloid Leukemia | Acute Myeloid Leukemia, in Relapse | NPM1 Mutation

Italy
Oryzon Genomics S.A.

Recruiting

Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+) (FRIDA)

Acute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia Refractory

United States
University Hospital, Antwerp

Recruiting

Treatment With ABT-199 (Venetoclax) and Purine Analogues in Relapsed/Refractory Acute Myeloid Leukemia

Acute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia Refractory

Belgium
Medical College of Wisconsin

Recruiting

Venetoclax to Augment Epigenetic Modification and Chemotherapy

Acute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia Refractory

United States
Ciceri Fabio
Associazione Italiana per la Ricerca sul Cancro; Gruppo Italiano Trapianto...

Recruiting

Analysis of the Immunobiology of Acute Myeloid Leukemia Relapses After Allogeneic Hematopoietic Stem Cell Transplant (HSCT) for the Generation of Guidelines and Personalized Therapeutic Pathways (GITMO-RELAPSE)

Acute Myeloid Leukemia, in Relapse

Italy
University of Pennsylvania

Active, not recruiting

CD123 Redirected T Cells for AML in Pediatric Subjects

Acute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia, Refractory | Acute Myeloid Leukemia, Pediatric

United States
Memorial Sloan Kettering Cancer Center

Recruiting

A Study of 19-28z/IL-18 in People With Acute Lymphoblastic Leukemia (ALL)

Refractory Acute Lymphoblastic Leukemia | Philadelphia-Negative ALL | Philadelphia-Positive ALL | Refractory Acute Lymphoblastic Leukemia (ALL) | Relapsed ALL, Adult | Refractory Acute Lymphoid Leukemia in Relapse

United States
Great Ormond Street Hospital for Children NHS Foundation...
Wellcome Trust

Recruiting

Base Edited CAR T Cells Against AML: Deep Conditioning Ahead of Allogeneic Stem Cell Transplantation (CARAML)

Relapsed Acute Myeloid Leukaemia

United Kingdom
Stanford University
Celgene Corporation

Terminated

Single Agent Lenalidomide in Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia

Leukemia | Relapsed Adult Acute Lymphocytic Leukemia

United States
M.D. Anderson Cancer Center

Not yet recruiting

Phase Ib/II Study Assessing the Clinical Activity and Safety of Brexucabtagene Autoleucel as a Consolidation in Patients With Relapsed/Refractory (R/R) and Newly Diagnosed B-cell Acute Lymphocytic Leukemia (ALL) Post Cytoreduction With Mini-HCVD-inotuzumab-blinatumomab/HCVAD-inotuzumab-blinatumomab

B-cell Acute Lymphocytic Leukemia | Relapsed/Refractory

United States
Federal Research Institute of Pediatric Hematology...

Recruiting

Ex-vivo Primed Memory Donor Lymphocyte Infusion to Boost Anti-viral Immunity After T-cell Depleted HSCT

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Acute Lymphoblastic Leukemia, in Relapse | Non-hodgkin Lymphoma | High Risk Acute Myeloid Leukemia | High Risk Acute Lymphoblastic Leukemia | Acute Biphenotypic Leukemia in Relapse

Russian Federation
Virginia Commonwealth University
Gilead Sciences

Withdrawn

Rituximab, Idelalisib, and Venetoclax in Relapsed/Refractory CLL/SLL (RIVe-CLL/SLL)

Chronic Lymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma | CLL | Refractory Small Lymphocytic Lymphoma | SLL | Relapsed CLL | Relapsed Chronic Lymphocytic Leukemia | Relapsed Small Lymphocytic Lymphoma
Shanghai Fosun Pharmaceutical Industrial Development...

Terminated

A Phase 1 Study to Evaluate FN-1501 Monotherapy in Patients With Advanced Solid Tumors and R/R AML

Advanced Cancer | Solid Tumors | Acute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia Refractory

United States, Australia
Beth Israel Deaconess Medical Center
Dana-Farber Cancer Institute

Active, not recruiting

A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia

Recurrent Adult Acute Myeloid Leukemia | Acute Myeloid Leukemia, in Relapse

United States
Menarini Group

Terminated

Study of MEN1112 Intravenous Infusion in Relapsed or Refractory Acute Myeloid Leukemia (ARMY)

Recurrent Adult Acute Myeloid Leukemia | Acute Myeloid Leukemia, in Relapse

France, Germany, Italy, Spain, Belgium
Institut de Recherches Internationales Servier
ADIR, a Servier Group company

Completed

Study of a New Intravenous Drug, Called S65487, in Patients With Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma or Chronic Lymphocytic Leukemia

Relapsed or Refractory Multiple Myeloma | Relapsed or Refractory Acute Myeloid Leukemia | Relapsed or Refractory Non-Hodgkin Lymphoma | Relapsed or Refractory Chronic Lymphocytic Leukemia

United Kingdom, Spain, France, Australia
University of Colorado, Denver
Karyopharm Therapeutics Inc

Recruiting

KPT-9274 in Patients With Relapsed and Refractory Acute Myeloid Leukemia

Acute Myeloid Leukemia | Acute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia Refractory

United States
Seattle Children's Hospital
2seventy bio

Recruiting

PLAT-08: A Study Of SC-DARIC33 CAR T Cells In Pediatric And Young Adults With Relapsed Or Refractory CD33+ AML

Acute Myeloid Leukemia | Acute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia Refractory

United States
First Affiliated Hospital of Wenzhou Medical University
Second Affiliated Hospital of Nanchang University; Hrain Biotechnology Co.,...

Unknown

Anti-CD19 CAR T Infusion Combined With Allogeneic Stem Cell Transplantation for B-cell Leukemia/Lymphoma

Hematopoietic/Lymphoid Cancer | Adult Acute Lymphoblastic Leukemia in Remission | B-cell Chronic Lymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia | B-cell Adult Acute Lymphoblastic Leukemia

China
Steven E. Coutre
Merck Sharp & Dohme LLC

Completed

Temozolomide Plus Vorinostat in Relapse/Refractory Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia With 11q23-abnormality in Relapse

United States
Caribou Biosciences, Inc.

Recruiting

CRISPR-Edited Allogeneic Anti-CLL-1 CAR-T Cell Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AMpLify)

Acute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia Refractory

United States
AstraZeneca
CLL Consortium

Completed

AZD6738 First Time in Patient Multiple Ascending Dose Study

B Cell Lymphomas | 11q-deleted Relapsed/Refractory Chronic Lymphocytic Leukaemia (CLL), | Prolymphocytic Leukaemia (PLL)

United States
Hospital Universitario San Ignacio
Pontificia Universidad Javeriana

Not yet recruiting

Evaluation of the Safety and Efficacy of Esperanza Extract (PA001) (PA001)

Acute Myeloid Leukemia | Colorectal Neoplasms | Pancreatic Neoplasms | Acute Leukemia | Acute Myeloid Leukemia, in Relapse | Neoplasm, Stomach | Gastric Neoplasms Malignant | Acute Leukemia in Relapse | Acute Leukemia Lymphoid

Colombia
University of Pennsylvania

Recruiting

Lentivirally Redirected CD123 Autologous T Cells in AML

Acute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia, Adult | Acute Myeloid Leukemia, Refractory

United States
Nationwide Children's Hospital

Not yet recruiting

Safety and Feasibility of CD19 CAR T Cells Using CliniMACS Prodigy for Relapsed/Refractory CD19 Positive ALL and NHL

Acute Lymphoblastic Leukemia, in Relapse | B Cell Leukemia | B-cell Non Hodgkin Lymphoma | Non-Hodgkin's Lymphoma, Relapsed | Non-Hodgkin's Lymphoma Refractory | Acute Lymphoblastic Leukemia With Failed Remission

United States

Clinical Trials on Leukemia Lymphocytic Acute (ALL) in Relapse

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Turkmenistan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations